William G. Wierda, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. William G. Wierda
CLL is a unique disease in which to do translational research because of the circulating tumor cells that can be sampled before, during and after treatment; providing the exceptional opportunity to study and confirm in vivo mechanisms of drug action and for hypothesis testing. MD Anderson Cancer Center (MDACC) is a uniquely established clinical Institution in which to perform translational research. Over three-fourths of patients with CLL are enrolled on clinical trial and provide tissue samples before, during, and after treatment for correlative studies. Most of the drugs currently approved for CLL have been developed and/or investigated at MDACC, including fludarabine, alemtuzumab, ofatumumab, and rituximab.
Dr. Wierda is uniquely qualified to be the Principal Investigator (PI) for this grant owing clinical and translational research and expertise in CLL. In 2001, Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC. He was promoted to Associate Professor of Medicine in 2007. In 2012, he was promoted to Professor of Medicine and continue clinical and translational research in CLL. Dr. Wierda’s outpatient clinical activities are more than 90% dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been PI, Co-PI, or collaborator on numerous clinical trials and conduct translational research in CLL. He has published many peer-reviewed articles on various clinical and translational aspects of CLL and drug development and have given numerous lectures on treatments for patients with CLL. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Present Title & Affiliation
Primary Appointment
Endowed Distinguished Professor Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Department Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Medical Director, Inpatient Medical Services, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief - Chronic Lymphocytic Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Center Medical Director, Department of Leukemia Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Wierda's research is in Chronic Lymphocytic Leukemia (CLL) prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, and developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Clinical Interests
Dr. Wierda's clinical interest is providing Chronic Lymphocytic Leukemia (CLL) patients with the best treatment options including immune and gene therapies, chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients.
Education & Training
Degree-Granting Education
| 1993 | University of Health Sciences/The Chicago Medical School, North Chicago, Illinois, US, MD |
| 1992 | University of Health Sciences/The Chicago Medical School, North Chicago, Illinois, US, Microbiology and Immunology, Ph.D |
| 1986 | University of California, Riverside, California, US, Biochemistry, BS |
Postgraduate Training
| 1996-1999 | Subspecialty Fellowship, Hematology and Oncology, University of California, San Diego, California |
| 1993-1996 | Internship and Residency, Internal Medicine, Duke University Medical Center, Durham, North Carolina |
Experience & Service
Academic Appointments
D.B. Lane Cancer Research Distinguished Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Associate Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012
Assistant Professor of Medicine, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2001 - 2007
Instructor, Department of Medicine, University of California San Diego, San Diego, CA, 1999 - 2001
Staff Physician, Department of Hematology and Oncology, San Diego Veterans Healthcare System, San Diego, CA, 1999 - 2001
Assistant Instructor of Immunology, Department of Immunology, UHS/School of Related Health Science, North Chicago, IL, 1989 - 1991
Administrative Appointments/Responsibilities
2025 iwCLL Program Planning Committee Member, iwCLL, 2024 - 2025
MDACC Incident Command, Patient Care Section Head, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Director, MDACC COVID Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Deputy Department Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Primary Lead, The University of Texas MD Anderson Cancer Center - CLL Moon Shot Program, Houston, TX, 2019 - Present
Executive Medical Director, Inpatient Medical Services, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Co-Lead, The University of Texas MD Anderson Cancer Center - CLL Moon Shot Program, Houston, TX, 2014 - 2019
Section Chief - Chronic Lymphocytic Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present
Center Medical Director, Department of Leukemia Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2009 - Present
Other Appointments/Responsibilities
Chair, MDACC Chapter of American Association of University Professors (AAUP), Houston, TX, 2022 - Present
President and CEO, CLL Global Research Foundation (CLLGRF), Houston, TX, 2019 - Present
Voting member, International Working Group for CLL (IWCLL), Cologne, 2019 - Present
Chair, NCCN-CLL and Hairy Cell Leukemia Panel, Houston, TX, 2017 - Present
Co-Chairman, NCCN - Non-Hodgkin's Lymphoma Panel, Houston, TX, 2009 - 2017
Organizer/Chairman - Leukemia Planning Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2013
Institutional Committee Activities
Committee Member, Brown Foundation Committee, 2024 - Present
Committee Member, Inpatient Patient Experience Committee meeting, 2023 - Present
Chair, Faculty Senate Welfare Committee, 2023 - Present
Committee Member, Institutional Survey Readiness Steering Committee (ISRSC), 2022 - Present
Committee Member, Transfer Center Committee, 2020 - Present
Committee Member, HAL's Expansion Operations Committee, 2020 - Present
Committee Member, Patient Flow Action Team, 2020 - Present
Committee Member, Service Line Learning Lab Committee, 2020 - Present
Committee Member, Inpatient Planning Committee, 2020 - Present
Committee Member, ICU Utilization and Goals of Care, 2020 - Present
Lead, COVID Floor Operations, 2020 - 2022
Committee Member, CCLT Covid Core Leadership Team, 2020 - Present
Committee Member, Discharge & Readmissions Patient Flow Team, 2020 - Present
Committee Member, Discharge Huddle Action Team, 2020 - Present
Committee Member, DoCM Executive Council, 2020 - Present
Co-Lead, MDACC Leukemia Service Line, 2020 - Present
Senator, MDACC Faculty Senate, 2019 - Present
Member, Promotion and Tenure Committee, 2019 - 2022
Co-Chair, Leukemia Planning Committee, 2019 - Present
Member, Executive Committee of the Faculty Senate, 2019 - 2022
Member, Patient Survey Governance, 2018 - Present
Member, Virtual Care Committee, 2018 - Present
Member, Promotions and Tenure Committee (PTC, 2018 - 2021
Co-Chair, Inpatient Operations Steering Committee, 2014 - Present
Member, Clinical Research Advisory Committee, 2014 - Present
Member, PRS Budget and Finance Committee, 2012 - 2015
Member, Soarian Project Operational Leadership Team, 2012
Chair, Administration and IT Subcommittee, 2011
Member, Productivity Work Group, 2011
Member, EMR Strategy Review Committee Strategic Vision and Goals Workgroup, 2011 - Present
Member, Ad Hoc Institutional Expense Analysis Steering Committee, 2011
Member, ICU Subcommittee, 2010 - Present
Member, 24 Hour Medical Coverage Steering Committee, 2010 - 2015
Member, Institutional Chemotherapy Biotherapy Policy Task Force, 2010 - Present
Chair, Clinical Research Committee, 2008 - 2011
Member, Institutional Animal Care and Use Committee, 2007 - 2008
Member, Clinical Research Committee, 2006 - 2012
Senator, Faculty Senate, 2005 - 2009
Member, Clinical Ethics Committee, 2005 - 2008
Member, Psychosocial, Behavioral, and Health Services Research Committee (PBHSRC), 2003 - 2006
Honors & Awards
| 2022 - 2024 | Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey |
| 2019 | President's Recognition of Faculty Excellence, The University of Texas MD Anderson Cancer Center |
| 2018 | 2018 Faculty Achievement Award in Patient Care, MD Anderson Cancer Center |
| 2017 - 2022 | D.B. Lane Cancer Research Distinguished Professor |
| 2017 | Melvin L. Samuels Award for Excellence in Patient Care, MD Anderson Division of Cancer Medicine |
| 2011 | Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine - UT MD Anderson Cancer Center |
| 2009 | Faculty Educator of the Month - December, The University of Texas M. D. Anderson Cancer Center |
| 2006 - 2011 | Clinical Scholar Award, Leukemia & Lymphoma Society |
| 1998 - 2000 | Clinical Fellowship Award, American Cancer Society |
| 1993 | Chicago Medical School Dean's Award for Service, The Chicago Medical School |
| 1992 | Nickerson Award for Excellence in Graduate Studies and Research, UHS/CMS |
| 1991 - 2024 | Alpha Omega Alpha Honor Medical Society |
| 1991 | Ben Blivaiss M.D./Ph.D. Travel Award, UHS/CMS |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 39(5):1058-1068, 2025. e-Pub 2025. PMID: 40108332.
- Veletic I, Harris DM, Rozovski U, Bertilaccio MTS, Calin GA, Takahashi K, Li P, Liu Z, Manshouri T, Drula RC, Furudate K, Muftuoglu M, Hossain A, Wierda WG, Keating MJ, Estrov Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia, 2025. e-Pub 2025. PMID: 40186065.
- Wierda WG. Highlights in chronic lymphocytic leukemia from the 66th ASH Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol 23 Suppl 1(1):3-13, 2025. e-Pub 2025. PMID: 39907565.
- Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica 110(1):78-91, 2025. e-Pub 2025. PMID: 39113656.
- Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica 110(1):92-102, 2025. e-Pub 2025. PMID: 39363864.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Kim E, Chen SS, Sivina M, Hwang H, Huang X, Ferrajoli A, Jain N, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood 144(25):2678-2681, 2024. e-Pub 2024. PMID: 39441901.
- Kismali G, Manyam G, Jain N, Ivan C, Lamothe B, Ayres ML, Iles LR, Wierda WG, Gandhi V. Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. Blood Cancer J 14(1):220, 2024. e-Pub 2024. PMID: 39695112.
- Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clin Lymphoma Myeloma Leuk 25(5):319-327, 2024. e-Pub 2024. PMID: 39710565.
- Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood 144(13):1374-1386, 2024. e-Pub 2024. PMID: 38861666.
- Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv 8(17):4487-4501, 2024. e-Pub 2024. PMID: 38968154.
- Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 11(9):e682-e692, 2024. e-Pub 2024. PMID: 39033770.
- Wierda WG. The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 22(6):291-293, 2024. e-Pub 2024. PMID: 39110651.
- Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv 8(10):2342-2350, 2024. e-Pub 2024. PMID: 38537065.
- Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Bottcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv 8(8):1992-2004, 2024. e-Pub 2024. PMID: 38290108.
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(3):175-204, 2024. e-Pub 2024. PMID: 38626800.
- Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
- Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma 64(9):1554-1561, 2023. e-Pub 2023. PMID: 37317991.
- Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402(10402):641-654, 2023. e-Pub 2023. PMID: 37295445.
- Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
- Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37648261.
- Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
- Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
- Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
- Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for >/=1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
- El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
- El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
- Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res 29(2):446-457, 2023. e-Pub 2023. PMID: 36346691.
- Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
- Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol 15(1):170, 2022. e-Pub 2022. PMID: 36494725.
- Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 63(12):2765-2784, 2022. e-Pub 2022. PMID: 35983732.
- Benjamin, R, Jain, N, Maus, MV, Boissel, N, Graham, C, Jozwik, A, Yallop, D, Konopleva, M, Frigault, M, Teshima, T, Kato, K, Boucaud, F, Balandraud, S, Gianella-Borradori, A, Binlich, F, Marchiq, I, Dupouy, S, Almena-Carrasco, M, Pannaux, M, Fouliard, S, Brissot, E, Mohty, M, Bonganay, L, Catt, L, Chappell, J, Cheung, G, Chu, V, Cuthill, K, Devereux, S, Dunlop, A, Ellard, R, Farzeneh, F, Folarin, N, Giemza, E, Kassam, S, Kazmi, M, Kuhnl, A, Lewis, J, Liskova, M, Mason, A, Metaxa, V, Mufti, G, Munro, H, Pagliuca, A, Patten, P, Potter, V, Jabbour, EJ, Kantarjian, HM, Kebriaei, P, Wierda, WG. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM). The Lancet Haematology 9(11):e833-e843, 2022. e-Pub 2022. PMID: 36228643.
- Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clin Cancer Res 28(20):4385-4391, 2022. e-Pub 2022. PMID: 35939599.
- Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
- Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
- Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
- Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278-3289, 2022. e-Pub 2022. PMID: 35196370.
- Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. e-Pub 2022. PMID: 35714675.
- Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J 12(5):80, 2022. e-Pub 2022. PMID: 35595730.
- Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
- Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 107(4):984-987, 2022. e-Pub 2022. PMID: 34937320.
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022. PMID: 34699592.
- Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res 20(2):280-292, 2022. e-Pub 2022. PMID: 34654720.
- Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica 107(1):292-297, 2022. e-Pub 2022. PMID: 34498444.
- Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol 12:833714, 2022. e-Pub 2022. PMID: 35273915.
- Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39(34):3853-3865, 2021. e-Pub 2021. PMID: 34618601.
- Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
- Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol 8(12):e912-e921, 2021. e-Pub 2021. PMID: 34735860.
- Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
- Esposito CL, Van Roosbroeck K, Santamaria G, Rotoli D, Sandomenico A, Wierda WG, Ferrajoli A, Ruvo M, Calin GA, de Franciscis V, Catuogno S. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. Cancers (Basel) 13(20), 2021. e-Pub 2021. PMID: 34680368.
- Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res 27(17):4690-4695, 2021. e-Pub 2021. PMID: 34083230.
- Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491-502, 2021. e-Pub 2021. PMID: 34097852.
- Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
- Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
- Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138(1):11-22, 2021. e-Pub 2021. PMID: 33827116.
- Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
- Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137(24):3327-3338, 2021. e-Pub 2021. PMID: 33786588.
- Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2021. PMID: 33087831.
- Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1129-1135, 2021. e-Pub 2021. PMID: 33327833.
- Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397(10277):892-901, 2021. e-Pub 2021. PMID: 33676628.
- Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
- Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma 62(1):224-228, 2021. e-Pub 2021. PMID: 32955970.
- O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11:720704, 2021. e-Pub 2021. PMID: 34858810.
- Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
- Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. e-Pub 2020. PMID: 32946567.
- Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
- Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2020. PMID: 31862959.
- Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Dohner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21):1859-1869, 2020. e-Pub 2020. PMID: 32267500.
- Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
- Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 135(15):1204-1213, 2020. e-Pub 2020. PMID: 31876911.
- Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(2):185-217, 2020. e-Pub 2020. PMID: 32023533.
- Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2020. PMID: 31005650.
Other Articles
- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 39(2):529, 2025. PMID: 39627506.
- Jain N, Wierda WG, O'Brien S Chronic lymphocytic leukaemia. Lancet 404(10453):694-706, 2024. PMID: 39068951.
- Cacace F, Iula R, De Novellis D, Caprioli V, D'Amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines 10(6), 2022. PMID: 35740427.
- Sharman JP, Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, Kater AP, Porro Lura M, Wierda WG A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem 3(2):492-506, 2022. PMID: 35846043.
- Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ The cure of leukemia through the optimist's prism. Cancer 128(2):240-259, 2022. PMID: 34614211.
- De Novellis D, Cacace F, Caprioli V, Wierda WG, Mahadeo KM, Tambaro FP The TKI Era in Chronic Leukemias. Pharmaceutics 13(12), 2021. PMID: 34959482.
- Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 35(11):3059-3072, 2021. PMID: 34168283.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. PMID: 33608690.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. PMID: 33731864.
- Abbas HA, Wierda WG Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021. PMID: 34055635.
- Tambaro FP, De Novellis D, Wierda WG The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. J Exp Pharmacol 13:923-935, 2021. PMID: 34744463.
- Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep 8(9):1678-1681, 2020. PMID: 32983475.
- Wierda WG, Tambaro FP How I manage CLL with venetoclax-based treatments. Blood 135(17):1421-1427, 2020. PMID: 32076705.
- Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Ann Emerg Med 75(2):264-286, 2020. PMID: 31561995.
- Tambaro FP, Wierda WG Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol 7(2):e168-e176, 2020. PMID: 32004486.
Editorials
- Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clin Cancer Res 29(14):2593-2601, 2023. PMID: 37282671.
- Wierda WG. Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment. NEJM Evid 1(7):EVIDe2200093, 2022. PMID: 38319264.
Book Chapters
- Wierda, WG. Promising combinations of drugs targeting apoptosis. In: Volume 1 - Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Wiley, 186-196, 2023.
- Strati, P, Konopleva, M, Wierda, WG. Cell Death, 191-200, 2022.
Letters to the Editor
- Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97: E201-E204, 2022.
- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 36: 1171-1175, 2022.
- Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL Jr, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97: E100-E102, 2022.
- Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations. Blood 138: 2589-2592, 2021.
- Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11: 25, 2021.
- Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135: 862-865, 2020.
- Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood 135: 510-513, 2020.
Selected Presentations & Talks
Local Presentations
- 2025. Evolving Strategies in CLL Treatment, Part 2. Invited. Leukemia Research Meeting. Houston, Texas, US.
- 2025. Evolving Strategies in CLL Treatments. Invited. Hematology Grand Rounds. Houston, Texas, US.
- 2024. Opportunities for Advances in CLL. Invited. Hematology Grand Rounds. Houston, Texas, US.
- 2019. Next Questions: Chronic Lymphocytic Leukemia. Conference. JWC Covenant, Inc. Houston, TX, US.
- 2019. Changing the treatment paradigm for CLL- Chemoimmunotherapy. Conference. CancerNet. Houston, TX, US.
- 2019. CLL Patient Forum. Conference. CLL Society. Houston, TX, US.
- 2018. Overview of CLL. Conference. Baylor College of Medicine. Houston, TX, US.
- 2018. Overview of Treatment Options for CLL. Conference. CancerNet. Houston, TX, US.
- 2017. CLL – Novel Strategies. Conference. MD Anderson Physicians Network. Houston, TX, US.
- 2017. Managing BTK Inhibitor Refractory CLL - A Case Study. Conference. Society of Hemotologic Oncology (SOHO). Houston, TX, US.
- 2016. How I Treat patients with High-Risk CLL. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2024. CLL. Invited. Hematology/Oncology Fellows Lecture Series, US.
- 2019. What Informs Our Clinical Decisions in CLL Management? Key Evidence to Stratify Risk and Optimize Sequencing. Conference. PER. Cranbury, NJ, US.
- 2019. CLL: An Overview. Conference. HOLI - Aptitude Health. Atlanta, GA, US.
- 2017. Value of MRD in CLL in Routine Practice. Conference. Canadian CLL Research Meeting. Winnipeg, CA.
National Presentations
- 2025. Updates in CLL. Invited. West Oncology Conference. Memphis, TN, US.
- 2024. Breyanzi Chronic Lymphocytic Leukemia KOL National Launch Meeting-Virtual. Conference. 2024 FL Strategic Council-Event. Virtual, US.
- 2023. Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study. Invited. Eli Lilly and Company. San Diego, CA, US.
- 2023. Pirtobrutinib, CAR T, and others. How to incorporate it in practice?. Conference. Binaytara Foundation. Nashville, TN, US.
- 2023. Novel Therapies of Ricters. Invited. Society of Hematologic Oncology (SOHO). Houston, TX, US.
- 2023. Treatment of Patients with P53 aberrantions. Invited. MD Education USA. La Jolla, CA, US.
- 2023. NCCN CLL/SLL/Hairy Cell Leukemia Panel Meeting. Conference. National Comprehensive Cancer Network (NCCN). Plymouth, PA, US.
- 2023. Chronic Lymphocytic Leukemia. Conference. 19th Miami Cancer Meeting. Miami, FL, US.
- 2023. Scientific Advisory Board- 2023 ONC Hematology Global Medical Scientific Advisory Board. Invited. Eli Lilly and Company. New York, NY, US.
- 2023. Physician Session Title: Emerging Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia. Invited. 20th Annual Indy Hematology Review. Indianapolis, IN, US.
- 2023. Moderator CLL: An Interactive Local Workshop. Invited. Curio Science. Virtual, US.
- 2022. Workup of CLL in the Era of Small Molecules - Breakfast with the Expert II. Invited. Society of Hematologic Oncology (SOHO 2022). Houston, TX, US.
- 2022. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic leukemia (Trial in Progress). Invited. Eli Lilly. Houston, TX, US.
- 2022. Moderator - AstraZeneca Optimizing CLL Treatment Selection in an Evolving Treatment Landscape Advisory Board. Invited. AstraZeneca. Houston, TX, US.
- 2022. Update on CLL Strategy. Conference. Roche, US.
- 2022. CLL - Immune Effectors, CAR-T, and Bispecific Therapies Across Heme Malignancies. Invited. Physicians' Education Resource (PER). New York, NY, US.
- 2022. Chair - Hematology Session III and Presentation: Learning from BTK Inhibitors & Moving Forward the Therapeutic Field in CLL. Invited. New Orleans Summer Cancer Meeting (NOSCM). New Orleans, LA, US.
- 2022. NCCN CLL/SLL/Hairy Cell Leukemia Panel Meeting. Invited. National Comprehensive Cancer Network (NCCN). Plymouth Meeting, PA, US.
- 2022. Answers Now: CLL Drug Resistance and Intolerance. Conference. Patient Power - videoconference, US.
- 2021. Chair: Elucidating Novel BTKi Strategies in CLL/SLL and MCL. Invited. Physicians' Education Resource (PER). Atlanta, GA, US.
- 2021. Chair - Medical Crossfire: How Are We Meeting the Needs of Patients with CLL Across Lines of Care. Invited. Physicians' Education Resource (PER). Houston, TX, US.
- 2021. Chronic Lymphocytic Leukemia. Invited. Appsvenue - Kuwait, US.
- 2021. Working Towards Curative Strategies for Patients with CLL. Invited. Fred Hutch/UW Medical Oncology and Clinical Research Division, US.
- 2021. Pharmacyclics Virtual Resistance Advisory Board. Invited. Pharmacyclics, Inc, US.
- 2021. Chair - MCL/ALL Regional Advisory Board. Invited. Kite Pharma, Inc, US.
- 2021. Medical Crossfire: What are the Key Patient and Tumor Specific Features that Drive Your Initial and Subsequent Decisions in CLL?. Invited. Physicians' Education Resource (PER), US.
- 2019. Present and Future Therapies for Chronic Lymphocytic Leukemia. Conference. MAYO Clinic. Rochester, MN, US.
- 2019. Evolving Strategies in First-Line CLL; Is there a Role for Chemoimmunotherapy?. Invited. NCCN. San Francisco, CA, US.
- 2019. "Relapsed/Refractory CLL/sLL Management". Conference. Medallion Healthcare. Dallas, TX, US.
- 2019. “The Changing Face of CLL Treatment - Moving with the Times”. Invited. Medscape Education. New York, NY, US.
- 2019. “Promises, Promises: Information Long-term Expectation in WM and CLL”. Conference. “Promises, Promises: Information Long-term Expectation in WM and CLL”. Chicago, IL, US.
- 2019. General disease state and treatment guidelines. Conference. Bio Ascend, LLC, AstraZeneca, Bayer, Celgene Corp, Gilead Sciences, US.
- 2019. Relapsed/Refractory Chronic Lymphocytic Leukemia: Cure or Long-Term Remission?. Invited. Physicians' Education Resource (PER). Miami, FL, US.
- 2019. Updates in CLL. Invited. Scripps Conference Services & CME. San Diego, CA, US.
- 2018. Assessment of R3esidual Disease (MRD): Should MRD be a milestone?. Conference. Leukemia Master Class. Dallas, TX, US.
- 2018. Cart-T MTP Session. Invited. SOHO, US.
- 2017. Review of current available evidence of the correlation between biomarker status in CLL and response to therapy and prognosis. Conference. Florida Cancer Specialist (FCS). Orlando, FL, US.
- 2017. How to Sequence Therapy in Chronic Lymphocytic Leukemia. Conference. NCCN Hematologic Malignancies Conference. San Francisco, CA, US.
- 2016. Assessing Key Factors when Choosing Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Invited. Chemotherapy Foundation Symposium. New York, NY, US.
- 2016. Debate—Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy. Invited. National Comprehensive Cancer Network. New York, NY, US.
- 2013. BTK Inhibitors, PI3K Inhibitors, Etc - Novel Therapies for CLL. Conference. 2013 ASH State-of-the-Art Symposium. Chicago, IL, US.
- 2013. Novel Agents in CLL. Invited. Society of Hematologic Oncology. Houston, TX, US.
- 2013. New Therapies. Invited. Society of Hematologic Oncology. Houston, TX, US.
- 2013. Core D Clinical Update. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). Coronado, CA, US.
- 2013. ROR1 CAR Update. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). Coronado, CA, US.
- 2012. CLL: Immunotherapy in CLL. Invited. Houston 2012 Hematologic Malignancies Conference. Houston, TX, US.
- 2012. MTP Session VIII: CLL Biology and Therapy - Biology and Prognostic Factors. Invited. Houston 2012 Hematologic Malignancies. Houston, TX, US.
- 2012. Utility of Prognostic and Predictive Factors in Management of Patients with CLL. Conference. 16th Annual Int'l Congress on Hematologic Malignancies. Snowbird, UT, US.
- 2012. Chronic Lymphocytic Leukemia (CLL). Invited. Leukemia & Lymphoma Society. Omaha, NE, US.
- 2012. Immune Stimulation. Conference. CLL Research Consortium (CRC) Annual Meeting. La Jolla, CA, US.
- 2012. Chronic Lymphocytic Leukemia. Conference. 2012 Highlights of ASH in North America. New York, NY, US.
- 2011. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL - Poster Presentation. Conference. American Society of Hematology Annual Meeting 2011. San Diego, CA, US.
- 2011. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyslosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL - Poster Presentation. Conference. American Society for Hematology Annual Meeting 2011. San Diego, CA, US.
- 2011. Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy - Poster Presentation. Conference. American Society of Hematology Annual Meeting 2011. San Diego, CA, US.
- 2011. State of the art and perspectives. Invited. XIV iwCLL 2011. Houston, TX, US.
- 2011. Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results. Conference. Society of Hematologic Oncology. Houston, TX, US.
- 2011. Impact of Bone Marrow Microenvironment on 93 Apoptotic Pathway Target mRNA Expression in CLL Cells. Conference. Society of Hematologic Oncology. Houston, TX, US.
- 2011. HDAC-Mediated Silencing of miR-17 and miR-20a in Chronic Lymphocytic Leukemia. Conference. Society of Hematologic Oncology. Houston, TX, US.
- 2011. Disease Characteristics and Response to First Therapy in African American Patients with CLL: the M.D. Anderson Cancer Center Experience. Conference. Society of Hematologic Oncology. Houston, TX, US.
- 2011. Sap+Cyclo+R (11q-). Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). La Jolla, CA, US.
- 2011. ROR-1 CAR. Conference. Chronic Lymphocytic Leukemia Research Consortium. La Jolla, CA, US.
- 2011. CRC Clinical Trial Concepts. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). La Jolla, CA, US.
- 2010. New Advances in CLL Management. Conference. 4th Annual Mid-America Cancer Symposium. Wichita, KS, US.
- 2010. Chronic Lymphocytic Leukemia: Novel Therapies. Conference. 2010 Highlights of ASH. Marina del Rey, CA, US.
- 2010. Risk Stratified Treatment for CLL. Conference. 6th Annual Clinical Breakthroughs & Challenges in Hamatologic Malignancies. Lake Buena Vista, FL, US.
- 2009. Emerging Agents for Chronic Lymphocytic Leukemia: Addressing Unmet Needs for Therapy. Conference. Physicians' Education Resource. Dallas, TX, US.
- 2009. New Treatments for CLL - Q & A. Invited. GlaxoSmithKline. Scottsdale, AZ, US.
- 2009. Update on Prognostic Factors and Current Treatments for Patients with Chronic Lymphocytic Leukemia (CLL). Invited. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
- 2009. Therapeutic Agents in CLL: Review and Discussion. Conference. Genentech, Inc. Dallas, TX, US.
- 2009. Focusing on CLL. Conference. Physicians' Education Resource. Dallas, TX, US.
- 2009. Review of clinical trial data (FC v FCR, PCR v FCR). Invited. National Comprehensive Cancer Network. Philadelphia, PA, US.
- 2009. Emerging Treatment Paradigms in the Management of Chronic Lymphocytic Leukemia. Invited. Educational Concepts Group, LLC. McKinney, TX, US.
- 2009. Symposium on Emerging Therapies in Lymphoproliferative Diseases: BCL-2 inhibitors. Invited. Great Debates and Updates in Hematologic Malignancies. Boca Raton, FL, US.
- 2009. Debate: No "Should CLL/SLL sub-groups that have deletion 17p or who have the best prognostic features be treated differently than the average CLL/SLL patient?. Invited. Great Debates and Updates in Hematologic Malignancies. Boca Raton, FL, US.
- 2009. Strategies for optimizing Rituxan clinical utility in CLL based on REACH and CLL-8 data. Invited. Genentech. Dallas, TX, US.
- 2009. ASH Review. Invited. University of Nebraska Medical Center. Omaha, NE, US.
- 2009. The development of Rituxan treatment in CLL including the initial monotherapy studies leading to combination treatment with fludarabine and subsequently fludarabine and cyclophosphamide. Invited. Regional Advisory Board/Review Article. Las Vegas, NV, US.
- 2008. Poster Presentation "Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease". Invited. American Society of Hematologists. San Francisco, CA, US.
- 2008. Poster Presentation "Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p". Invited. American Society of Hematologists. San Francisco, CA, US.
- 2008. Poster Presentation "CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p". Invited. American Society of Hematologists. San Francisco, CA, US.
- 2008. Poster Presentation "Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy". Invited. American Society of Hematologists. San Francisco, CA, US.
- 2008. Rituxan in the treatment of CLL. Invited. Genentech Advisory Board Moderator Workshop. San Francisco, CA, US.
- 2008. Emerging Treatment Paradigms in the Management of CLL. Invited. Meeting of the Division of Neoplastic Diseases & Related Disorders. Milwaukee, WI, US.
- 2008. Prognostic Factors - Directing Treatment Strategies. Invited. Leukemia 2008. Houston, TX, US.
- 2008. 406 Study Background: Unmet Need in Fludarabine Refractory CLL. Invited. Leukemia 2008. Houston, TX, US.
- 2008. Advisory Panel Member. Invited. NCCN Non-Hodgkin's Lymphoma Panel Meeting. Philadelphia, PA, US.
- 2008. Advisor. Invited. Abraxis Bioscience Pipeline Council Meeting. Los Angeles, CA, US.
- 2008. The Role of Revlimid (lenalidomide) in del 5q Myelodysplastic Syndromes. Invited. Revlimid Promotional Speakers Bureau Meeting. Houston, TX, US.
- 2008. Expanding Horizons: Advances in Targeted Therapies for CLL. Invited. Campath Promotional Dinner Meeting. Costa Mesa, CA, US.
- 2008. CD20 Scientific Platform - Part 1 and Part 2. Invited. 2008 Genentech Advisory Initiative: NHL Regional Academic Meeting. Dallas, TX, US.
- 2008. Advances in the Treatment of CLL. Invited. American Society of Clinical Oncologists (ASCO). Chicago, IL, US.
- 2008. Illuminating Possibilities: Making Strides in the Treatment of B-cell Chronic Lymphocytic Leukemia (B-CLL). Invited. Campath Promotional Speakers Bureau Meeting. Mobile, AL, US.
- 2008. Emerging Treatment Paradigms in the Management of CLL. Invited. CLL Content Development Session 2008. New York, NY, US.
- 2008. Future Development of Rituxan. Invited. CLL National Advisory Board Meeting. Dallas, TX, US.
- 2008. Lumilixamab. Invited. Lumiliximab Academic Steering Committee Meeting. La Jolla, CA, US.
- 2008. Chronic Lymphicytic Leukemia (CLL) Induction: How Hard to Push?. Invited. Duke Debates - Controversies in the Management of Patients with Hematologic Malignancies. Asheville, NC, US.
- 2008. Clinical Issues and Future Directions in Hematologic Malignancies. Invited. Post-ASH Regional Meeting. San Francisco, CA, US.
- 2008. Management of CLL and CML. Invited. 4th Annual Cancer Treatment Options. Newport Beach, CA, US.
- 2008. What's New in the Management of Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma, and Myeloma. Houston, TX, US.
- 2008. Chemotherapeutic Options: Has Standard Therapy Changed?. Invited. 4th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies. Tampa, FL, US.
- 2007. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. Invited. American Society of Hematology - 2007 Annual Meeting. Atlanta, GA, US.
- 2007. Optimizing Campath Use to Improve Outcomes in CLL & Future Directions. Invited. ION PACT Meeting. Tysons Corner, VA, US.
- 2007. Anti B-cell Therapies. Invited. Medimmune Advisory Board Meeting. Gaithersburg, MD, US.
- 2007. Combination Strategies for Up-front and Early Relapsed Patients. Invited. Indolent Lymphoma Workshop. Arlington, VA, US.
- 2007. Combination Strategies for Up-Front and Early Relapsed Patients. Invited. Lymphoma Research Foundation, Indolent Lymphoma Workshop. Washington, DC, US.
- 2007. New Treatment Modalities: Recognize the Role of Targeted Therapy in the Treatment of CLL. Invited. 1st Annual Milton & Dawn Gilman Leukemia & Lymhoma Symposium. Royal Oak, MI, US.
- 2007. CLL: New Approaches for High-Risk Patients. Invited. Third Annual Oncology Congress. San Francisco, CA, US.
- 2007. Review and Discussion of CLL Case Study. Invited. Rituxan Advisory Initiative. Atlanta, GA, US.
- 2007. B-Cell Malignancies Education Network - Focus on Chronic Lymphocytic Leukemia. Invited. B-Cell Malignancies Education Network - Focus on Chronic Lymphocytic Leukemia. Wichita Falls, TX, US.
- 2007. Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma & Myeloma Series 2007. Los Angeles, CA, US.
- 2006. Updates in CLL: Prognostic Markers and Their Implication for Treatment Strategies. Conference. 48th Annual American Society of Hematology. Orlando, FL, US.
- 2006. Chronic Lymphocytic Leukemia. Invited. Grand Rounds. Boston, MA, US.
- 2006. Chronic Lymphocytic Leukemia. Invited. CLL Grand Rounds. Cincinnati, OH, US.
- 2005. Chronic Lymphocytic Leukemia. Invited. II Reunion Hematologia 2005. Las Palmas.
- 2005. Chronic Lymphocytic Leukemia. Invited. IWCLL Meeting. New York, NY, US.
- 2005. Title not provided. Invited. Texas Hematology-Oncology Center. Dallas, TX, US.
- 2005. 2005 Rituxan Consultant Initiative. Invited. 2005 Rituxan Consultant Initiative. Chicago, IL, US.
- 2005. 2005 Rituxan Consultant Initiative. Invited. 2005 Rituxan Consultant Initiative. New York, NY, US.
- 2005. Chronic Lymphocytic Leukemia. Invited. CMI-certified PeerView Webcast, US.
- 2005. Chronic Lymphocytic Leukemia. Invited. CME-certified PeerView Webcast, US.
- 2005. Meet the Experts on Chronic Lymphocytic Leukemia. Invited. Leukemia / Lymphoma Symposium, Patient Education. San Diego, CA, US.
- 2005. Patient Education: Meet the Experts on Chronic Lymphocytic Leukemia. Invited. Leukemia / Lymphoma Symposium. San Diego, CA, US.
- 2005. Current Trends in Leukemia, Lymphoma, and Myeloma. Invited. A Post-ASH Update. New York, NY, US.
- 2005. Current Trends in Leukemia, Lymphoma, and Myeloma:. Invited. A Post-ASH Update. Kansas City, MO, US.
- 2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. NOCR Lymphoma Key Opinion Leader Meeting. Chicago, IL, US.
- 2004. Chronic Lymphocytic Leukemia (CLL). Invited. Leukemia 2004 Congress Towards the Cure. Houston, TX, US.
- 2004. Pediatrics. Invited. Leukemia 2004 Congress Towards The Cure. Houston, TX, US.
- 2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. Grand Rounds. Jonesboro, AR, US.
- 2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. 4th Annual B.C. Community Oncology Meeting. Vancouver, US.
- 2004. New Treatments for Patients with Chronic Lymphocytic Leukemia. Invited. ASH 2003 Highlights. Philadelphia, PA, US.
- 2004. Overview of Recently Released Data on Monoclonal Antibody Therapy for B-Cell Malignancies. Invited. CME-Roundtable Dinner Meeting. Oklahoma City, OK, US.
- 2004. Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma and Myeloma. Dallas, TX, US.
- 2003. Cytogenetics in CLL. Invited. Advanced Leukemia Practitioner Journal Club. Houston, TX, US.
- 2003. Variant Lymphoid Leukemias. Invited. Advanced Leukemia Practitioner Journal Club. Houston, TX, US.
- 2003. Treatment of Chronic Lymphocytic Leukemia. Invited. Genentech CME Dinner Program. Visalia, CA, Bakersfield, CA, Fresno CA and Thousand Oaks, CA, 9/2003, US.
- 2003. Monoclonal Antibodies and Their Use in the Treatment of Hematologic Malignancies. Invited. CME-Roundtable Dinner Meeting. Orlando, FL, US.
- 2003. The Evolution of IL-2R Targeted Therapy for Hematologic Malignancie. Invited. 2003 Pan-Pacific Lymphoma Conference, CME-certified satellite symposium. Mauna Lani, HI, US.
- 2003. Treatment of CLL. Invited. Lymphoma Symposium, Aultman Institute. Cleveland, OH, US.
- 2003. Rituximab-based regimens in CLL. Invited. Current Trends in Leukemia, Lymphoma & Myeloma. San Francisco, CA, US.
- 2003. Monoclonal Antibodies and Their Use in the Treatment of Hematologic Malignancies. Invited. Hem/Onc Physicians Meeting. San Diego, CA, US.
- 2003. Treatment of CLL. Invited. Grand Rounds, Mamie McFadden Ward Cancer Center. Beaumont, TX, US.
- 2003. A potential new therapy for CLL. Invited. HealthStream Web Event Teleconference. Nashville, TN, US.
- 2003. Rituximab in treatment of CLL. Invited. Rituxan Community Advisory Board Meeting. Berkley, CA, US.
- 2002. Rituximab in Management of CLL. Invited. Genentech/IDEC Round Table Discussion – CLL. Tampa and Orlando, FL, US.
- 2002. Current Advances in Treatment of CLL. Invited. Clinical Advances in Leukemia and Lymphoma. Santa Ana Pueblo, NM, US.
- 2001. Gene therapy and future immunotherapies for CLL. Invited. Clinical Advances in Chronic Lymphocytic Leukemia Conference. Las Vegas, NV, US.
International Presentations
- 2025. Management of Relapsed/Refractory CLL and New Treatments on the Horizon. Conference. 3rd SOHO Israel Annual Meeting. Virtual, IL.
- 2024. What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia- What Clinicians Want to Know. Invited. ASH 2024. San Diego, US.
- 2024. CLL. Invited. AbbVie Global CLL Advisory Council Meeting at ASH. San Diego, US.
- 2024. Is Continuous Therapy the Best Option for High-Risk Patients. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
- 2024. Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
- 2024. Is Continuous Therapy the Best Option for High-Risk Patients. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
- 2024. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Poster. 12th Annual Meeting of the Society of Hematologic Oncology. Houston, US.
- 2024. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Poster. 12th Annual SOHO Meeting. Houston, US.
- 2024. Oral Poster -Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Invited. ASCO 2024. Chicago, US.
- 2024. Novel Treatments on the Horizon for CLL. Invited. Tel Aviv Universtiy. TelAviv, IL.
- 2024. Optimizing first-line treatment outcomes for patients with CLL. Invited. SOHO Isreal Meeting & International Davidoff Conference, IL.
- 2024. Defined Duration vs MDR Driven Time-limited Therapy - Webcast. Invited. EHA. Vienna, AT.
- 2024. What roll will non-covalent BTK inhibitors play? - Webcast. Conference. EHA. Vienna, AT.
- 2023. Poster - P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. Conference. EHA. Frankfurt, US.
- 2023. Poster - P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY. Conference. EHA. Frankfurt, US.
- 2023. Poster- P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). Conference. EHA. Frankfurt, US.
- 2023. S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. Conference. S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. FrankFurt, US.
- 2023. Evolving Concepts in CLL- Decisions at Diagnosis: Incorporating Disease Factors and Biomarkers. Conference. AbbVie. Frankfurt, DE.
- 2023. B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence. Invited. Physicians' Education Resource (PER). Chicago, US.
- 2023. Oral Poster - Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Conference. ASCO. Chicago, US.
- 2023. Defying Odds with Innovation in CLL: Perspectives on Personalized Care, Multi-Agent Platforms,and Sequential Targeted & Cellular Strategies. Invited. PeerView Institute. Chicago, US.
- 2023. Chronic Lymphoid Leukemia Frontline Treatment. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
- 2023. CLL Relapsed/Refractroy & Novel Agents. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
- 2023. Frontline Therapies. Invited. SOHO 23 Turkiye. Istanbul, TR.
- 2023. Management of Relapsed/Refractory Disease: Novel Agents. Conference. SOHO 23 Turkiye. Istanbul, TR.
- 2023. BTK Inhibitors in CLL: Monotherapy Trials. Invited. DAVA Oncology. Whistler, CA.
- 2022. MRD as an endpoint?. Invited. German CLL Study Group. Cologne, DE.
- 2022. Program Director - Applications of Individualized Treatment Strategies for CLL/SLL Symposium. Invited. Clinical Education Alliance. Chicago, US.
- 2022. Chronic Lymphocytic Leukemia (CLL) Steering Committee. Invited. Abbvie. Chicago, US.
- 2022. Fixed-duration (FD) Ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 3-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. Invited. PCYC. Chicago, US.
- 2021. Chair and Moderator - Prognostic markers session. Invited. German CLL Study Group, US.
- 2019. "The role of CAR-T cells in relapsed-refractory adult ALL and CLL". Invited. AORN Santobono-Paulislipon. Naples, IT.
- 2018. Updates on Hematology. Invited. AMGEN. Bogota, CO.
- 2018. Bringing future today: Venetoclax in the management of the 1st relapse setting in CLL. Invited. 29th Pan-Hellenic Congress of Hematology. Thessaloniki, GR.
- 2018. Combining treatment modalities: useful or superfluous?. Conference. ERIC International Meeting. Barcelona, ES.
- 2018. Is minimal residual disease as significant in chronic leukemias as it is in acute leukemias?. Invited. Dubrovnik Program, HR.
- 2018. Venetoclax + ibrutinib. Invited. Annual Canadian CLL Meeting. Winnipeg, CA.
- 2018. Treatment for Relapsed CLL after CIT. Conference. ASCO. Chicago, US.
- 2018. Sequencing of New Therapies in CLL. Conference. International Ultmann Chicago Lymphoma Symposium. Chicago, US.
- 2018. BCL-2 inhibitors in CLL. Conference. International Symosium on CLL. Venice, IT.
- 2018. Choice of First-Line Therapy for CLL: How to Select and What Are the Prioritized Objectives?. Conference. 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma. Hollywood, US.
- 2017. ABT199 during the Chronic Lymphocytic Leukemia. Conference. International Association for Comparative Research on Leukemia and Related Diseases Symposium (IACRLRD). Houston, US.
- 2017. Assessing Key Factors when Choosing Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Conference. International Association for Comparative Research on Leukemia and Related Diseases Symposium (IACRLRD). Houston, US.
- 2017. CLL Treatment Goals. Invited. Lebanese Society of Hematology and Blood Transfusion. Beirut, LB.
- 2017. Today's Cancer Treatment: How Individualized Can It Be?. Conference. Cancer Crosslinks 2017. Oslo, NO.
- 2016. State-of-the-Art in Frontline Treatment of Patients with Chronic Lymphocytic Leukemia. Invited. European Congress on Hematology: Focus on Lymphoid Malignancies. Paris, FR.
Formal Peers
- 2024. Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know. San Diego, CA, US.
- 2024. Chronic Lymphocytic Leukemia, US.
- 2024. Opportunities for Advances in CLL. Houston, TX, US.
- 2024. Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care. Houston, TX, US.
- 2024. Continuing Education on CLL, US.
- 2024. Fixed-Duration: A Patient-Captivating Standard of Care in CLL. Web-Based Activity on CLL, US.
- 2024. Future therapies including CAR-T therapies/Lead Meet the Expert. Vienna, AT.
- 2024. Chronic Leukemia. Visiting. Houston, TX, US.
- 2023. 2023 Hematology Highlights: A Post ASH Review. Invited. Omaha, NE, US.
- 2017. CD20 Targeting with Rituximab and Newer Approaches. Invited. Houston, TN, US.
- 2016. Developments in the Management of Chronic Lymphocytic Leukemia. Invited. Milwaukee, WI, US.
- 2016. Navigating the Therapeutic Options in Chronic Lymphocytic Leukemia. Invited. Atlanta, GA, US.
- 2016. Update of Management for CLL. Invited. Hackensack, NJ, US.
- 2012. New Antibodies for the Treatment of CLL and Lymphoma. Invited. Stockholm, SE.
- 2011. Opportunities for Advancing Treatments for Patients with CLL. Visiting. New York City, NY, US.
- 2009. Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Visiting. Houston, TX, US.
- 2009. 2009 Hematology Highlights: A Post ASH Review - CLL. Invited. Omaha, NE, US.
- 2008. Clinical Research in CLL: Making New Treatments Available to Patients in Houston. Visiting. Houston, TX, US.
- 2007. New Treatment Modalities: Recognize the Role of Targeted Therapy in the Treatment of CLL. Invited. Royal Oak, MI, US.
- 2007. Improving Outcomes in All Stages of CLL - Interpreting Recept Research. Invited. Quebec City, Quebec, CA.
- 2007. Future Directions in the Management of CLL. Invited. Windsor, CA.
- 2007. Management of Resistant CLL. Invited. Toronto, CA.
- 2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. London, CA.
- 2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. Hamilton, CA.
- 2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. Ontario, CA.
- 2007. Use of Rituximab in CLL, both as a single agent and in combination. Invited. Sao Paulo, BR.
- 2007. CLL and Hairy Cell Leukemia. Invited. Houston, TX, US.
- 2006. Chronic Lymphocytic Leukemia. Invited. Winnipeg, CA.
- 2006. CLL. Invited. Winnipeg, CA.
- 2006. Grand Rounds. Invited. Boston, MA, US.
- 2006. Grand Rounds. Invited. Cincinnati, OH, US.
- 2005. CLL and Gene Therapy. Invited. Melbourne, AU.
- 2005. CME Certified PeerView Webcast. Invited, FL, US.
- 2005. Patient Education: Meet the Experts on Chronic Lymphocytic Leukemia. Invited. San Diego, CA, US.
- 2003. Treatment of CLL. Invited. Columbia, SC, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | 2023-0106 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies |
| Funding Source: | AbbVie |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Pending |
| Role: | Collaborator |
| ID: | FP00017140 |
| Date: | 2023 - Present |
| Title: | 2022-0055 A PHASE IB OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| Funding Source: | Genentech Inc |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | 2019-0565: A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL) |
| Funding Source: | AstraZeneca |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | 2019-0565: A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL) |
| Funding Source: | Genentech |
| Role: | PI |
| Date: | 2018 - 2025 |
| Title: | 2018-0850 A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL) |
| Funding Source: | LoxoOncology |
| Role: | Principal Investigator-MDACC |
| Date: | 2018 - 2025 |
| Title: | 2018-0316: A phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
| Funding Source: | Cyclacel |
| Role: | PI |
| ID: | Pending |
| Date: | 2018 - 2019 |
| Title: | 2015-0651 A Phase 1 does-ranging study to investigate the safety, tolerability, and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous injection, and intravenous Administration in Subjects with Various Lymphomas and Leukemias |
| Funding Source: | MiRagen, Inc |
| Role: | PI |
| ID: | 00006439 |
| Date: | 2018 - 2024 |
| Title: | 2017-0889: A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies |
| Funding Source: | Oncternal Therapeutics, Inc |
| Role: | PI |
| ID: | CIRM0001/MDACC55474 |
| Date: | 2018 - 2024 |
| Title: | 2017-0751: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Funding Source: | Juno Therapeutics, Inc |
| Role: | PI |
| ID: | 17004-JCAR17/MDACC55252 |
| Date: | 2017 - 2019 |
| Title: | 2016-0341 A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced with Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia |
| Funding Source: | Ziopharm, Inc |
| Role: | Principal Investigator-MDACC |
| ID: | CD-33/MDACC54419 |
| Date: | 2017 - 2019 |
| Title: | 2017-0158 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton?s Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies |
| Funding Source: | Sunesis |
| Role: | PI |
| ID: | 062HEM102/MDACC55252 |
| Date: | 2017 - 2024 |
| Title: | 2016-0875: Phase II Study of the Combination of Ibrutinib Plus Venetoclax in Subjects with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Funding Source: | Pharmacyclics, Inc |
| Role: | PI |
| ID: | PCYC-1142-CA/MDACC005459 |
| Date: | 2017 - 2021 |
| Title: | 2016-0991: A Phase 1 Multidose Study To Evaluate the Safety and Tolerability of Xmab 13676 in Patients with Cd20-Expressing Hematologic Malignancies |
| Funding Source: | Xencor |
| Role: | PI |
| ID: | XmAb1367601/MDACC54273 |
| Date: | 2016 - 2018 |
| Title: | 2015-0416 A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) |
| Funding Source: | Kite Pharma, Inc |
| Role: | PI |
| ID: | KTE-C19-103/MDACC51552 |
| Date: | 2015 - 2022 |
| Title: | 2015-0416: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) |
| Funding Source: | Kite Pharma |
| Role: | PI |
| ID: | CS2018-00051552-AM1-RP |
| Date: | 2015 - 2018 |
| Title: | 2014-0601: A Phase 2 Study of the Safety & Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export Selinexor in Patients with Refractory and/or Relapsed Richter's Transformation |
| Funding Source: | Karypharm |
| Role: | PI |
| ID: | 12843 |
| Date: | 2014 - 2019 |
| Title: | 2014-0405: A Phase 2 Open-Label Study of the Efficacy & Safety of ABT-199 (GDC-0199) in CLL Subjects w/ Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy |
| Funding Source: | AbbVie |
| Role: | PI |
| ID: | M14-032/MDACC39301 |
| Date: | 2014 - 2019 |
| Title: | 2013-0486: A Phase IB Multicenter Dose-Finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia |
| Funding Source: | Genentech, Inc |
| Role: | PI |
| ID: | GP28331/MDACC38644 |
| Date: | 2014 - 2019 |
| Title: | 2014-0419 A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia |
| Funding Source: | Acerta Pharma, LLC |
| Role: | PI |
| ID: | ACE-CL-002/MDACC39286 |
| Date: | 2014 - 2015 |
| Title: | Creating Novel Translation Inhibitors to Target Pro-survival Oncoproteins |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP130660 |
| Date: | 2014 - 2017 |
| Title: | 2012-0912: A Phase I Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
| Funding Source: | Tragara |
| Role: | PI |
| ID: | 7837 |
| Date: | 2014 - 2019 |
| Title: | 2013-0907 A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia |
| Funding Source: | Acerta Pharma, LLC |
| Role: | PI |
| ID: | ACE-CL001/MDACC38195 |
| Date: | 2013 - 2018 |
| Title: | 2013-0315: A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion |
| Funding Source: | AbbVie |
| Role: | PI |
| ID: | M13-982/MDACC37869 |
| Date: | 2013 - 2017 |
| Title: | SCOR: Next-Generation T-Cell Leukemia Trial Targeting ROR1 on CLL |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Project Leader |
| ID: | 01 |
| Date: | 2013 - 2016 |
| Title: | Attacking the specific vulnerability of LKB1-mutant NSCLC to energy depletion using an ATP mimetic |
| Funding Source: | V Foundation for Cancer Research |
| Role: | Co-I |
| ID: | 01 |
| Date: | 2013 - 2017 |
| Title: | 2012-0626 A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab or in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia |
| Funding Source: | Emergent BioSolutions, Inc |
| Role: | PI |
| ID: | 0000733 |
| Date: | 2013 - 2017 |
| Title: | LAB03-0893 Cellular Therapy for CLL Utilizing Chimeric Antigen Receptors (CARs) |
| Funding Source: | CLL Global Research Foundation |
| Role: | PI |
| ID: | 01 |
| Date: | 2012 - 2019 |
| Title: | 2012-0411 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia |
| Funding Source: | Gilead Sciences, Inc |
| Role: | PI |
| ID: | US-312-0115/MDACC40192 |
| Date: | 2012 - 2018 |
| Title: | Chronic Lymphocytic Leukemia Research Consortium Core D |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5 P01 CA081534-16 Core D |
| Date: | 2012 - 2017 |
| Title: | Chronic Lymphocytic Leukemia Research Consortium Core D multi |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 5 P01 CA081534-13 Core D multi |
| Date: | 2012 - 2018 |
| Title: | 2012-0171L A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia |
| Funding Source: | Gilead Sciences, Inc |
| Role: | PI |
| ID: | US-312-0117/MDACC40194 |
| Date: | 2012 - 2018 |
| Title: | 2012-0707 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Funding Source: | Pharmacyclics, Inc |
| Role: | PI |
| ID: | PCYC-1112-CA/MDACC37082 |
| Date: | 2012 - 2016 |
| Title: | Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 R01 CA163802-02 |
| Date: | 2012 - 2019 |
| Title: | 2011-0142L A Long-Term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia |
| Funding Source: | Pharmacyclics, Inc |
| Role: | PI |
| ID: | PCYC1112/MDACC00969508 |
| Date: | 2012 - 2021 |
| Title: | 2011-0164: A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Funding Source: | Abbott |
| Role: | PI |
| ID: | M12-175/MDACC34768 |
| Date: | 2012 - 2018 |
| Title: | 2011-0612 An Extention Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects with Hematologic Malignancies |
| Funding Source: | Gilead Sciences, Inc |
| Role: | PI |
| ID: | CAL 101-99/MDACC969261 |
| Date: | 2011 - 2017 |
| Title: | 2010-0516: A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH |
| Funding Source: | Cyclacel |
| Role: | PI |
| ID: | MDACC34318 |
| Date: | 2010 - 2020 |
| Title: | 2010-0241: Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients with CLL |
| Funding Source: | GlaxoSmithKline |
| Role: | PI |
| ID: | COMB157BUS14T/OFT113592/Ofatumumab/MDACC32628 |
| Date: | 2010 - 2016 |
| Title: | 2010-0123: A Phase II Trial of Eltrombopag for Patients with Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia |
| Funding Source: | GlaxoSmithKline |
| Role: | PI |
| ID: | ELT113559/MDACC32388 |
| Title: | 2018-0302 A phase I/Ib pilot study of Combined Trabectedin and Venetoclax in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK inhibitor |
| Funding Source: | MDACC/Janssen |
| Role: | Co-PI |
| Title: | IL15-Secreting Armored CAR-NK cells Targeting CD19+ Cancers |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | Collaborator |
| ID: | Proposal: FP00005072 |
Patient Reviews
CV information above last modified May 16, 2025